GlaxoSmithKline announced it has begun shipping the 2015–2016 formulation of Fluarix Quadrivalent (influenza virus vaccine) and expects to begin shipping Flulaval Quadrivalent (influenza virus vaccine) in August to healthcare providers.
The company also made the decision to switch to 100% quadrivalent formulations following customer demand from the 2014–2015 flu season and early pre-booking for this season. Quadrivalent vaccines are designed to help protect against two different types of “A” flu strains and two types of “B” flu strains.
Both Fluarix Quadrivalent and Flulaval Quadrivalent are approved for use in adults and children aged ≥3 years for active immunization for the prevention of influenza disease caused by the virus subtypes A and B contained in the vaccine.
Fluarix Quadrivalent is supplied as a 0.5mL single-dose, prefilled syringe. Flulaval Quadrivalent is supplied as a 5mL, multi-dose vial containing 10 doses.
For more information call (888) 825-5249 or visit GSK.com.